Tirzepatide is a dual agonist of GLP-1 and GIP receptors, developed by Eli Lilly. It is associated with the medicines Mounjaro and Zepbound for diabetes and obesity. The page reviews weight-management and diabetes research, including the SURMOUNT trial program, alongside preliminary questions about cardiovascular outcomes and dual-incretin signaling.
GLP-1 receptor agonism provides appetite suppression through hypothalamic circuits, glucose-dependent insulin secretion, and slowed gastric emptying. GIP receptor agonism adds enhanced post-meal insulin and glucagon responses, improved beta cell function (GIP is trophic for beta cells), direct adipose tissue effects, and reduction of GLP-1-associated nausea through GIP receptor-mediated brainstem signaling.
Tirzepatide (Mounjaro for T2D, Zepbound for obesity) is a once-weekly injectable dual agonist of GLP-1 and GIP (Glucose-dependent Insulinotropic Polypeptide) receptors developed by Eli Lilly — the first approved pharmaceutical targeting both incretin receptors simultaneously. It produces mean weight losses of 20–22% of body weight at the highest dose in the SURMOUNT trials — making it the most effective pharmacological weight-loss agent ever approved.
Quick Reference
Member reference tables summarize the compound's research parameters.
GLP-1 receptor agonism provides appetite suppression through hypothalamic circuits, glucose-dependent insulin secretion, and slowed gastric emptying. GIP receptor agonism adds enhanced post-meal insulin and glucagon responses, improved beta cell function (GIP is trophic for beta cells), direct adipose tissue effects, and reduction of GLP-1-associated nausea through GIP receptor-mediated brainstem signaling. The combination produces additive weight loss and glycemic control beyond what either receptor alone achieves.
Clinical Results
SURMOUNT-1 (obesity, non-diabetic): 20.9% mean body weight reduction at 72 weeks at 15mg. SURPASS-2 head-to-head versus semaglutide 1mg showed tirzepatide produced greater HbA1c reduction and weight loss at all doses. In SURMOUNT-3 (after intensive lifestyle run-in): 26.6% weight loss — approaching results of bariatric surgery.
Research Indications
Weight Loss
Supported Research
Severe Obesity Management
Clinical trials demonstrate 15-22% body weight reduction in non-diabetic obese individuals - superior to all existing weight loss medications including semaglutide
Metabolic Syndrome Reversal
Comprehensive improvement in waist circumference, blood pressure, triglycerides, HDL cholesterol, and insulin resistance markers
Body Composition Optimization
Preferentially reduces visceral adipose tissue while preserving lean muscle mass when combined with resistance training and adequate protein
Diabetes
Supported Research
Type 2 Diabetes Management
FDA-approved for T2DM with superior HbA1c reduction (1.5-2.4%) compared to existing GLP-1 agonists and insulin regimens
Insulin Resistance Improvement
Significantly improves insulin sensitivity indices and glucose tolerance in prediabetic, diabetic, and metabolically healthy obese populations
Beta Cell Preservation
Protects pancreatic beta cell function and may help restore glucose-responsive insulin secretion in early diabetes
Cardiovascular
Preliminary Data
Cardiovascular Risk Reduction
SURPASS-CVOT trial showed 26% reduction in major adverse cardiovascular events in high-risk diabetic patients
Blood Pressure Management
Significant reductions in both systolic (8-12 mmHg) and diastolic blood pressure independent of weight loss effects
Lipid Profile Enhancement
Improves triglycerides (-20-30%), increases HDL cholesterol, reduces small dense LDL particles and apolipoprotein B
Research Protocols
As reported in cited literature and research-community logs (see Research Citations below), not a personal dosing recommendation.
This member section describes parameters reported in the research literature.
Included for harm-reduction awareness only, in the event this compound is encountered outside its labeled research use. Inclusion here does not imply RUO Codes endorses, recommends, or instructs human use.
This member section discusses research safety considerations and uncertainties.
Licensed Source or Registered 503B Compounding Facility
The listed research text specifies confirming the product originates from a licensed pharmacy or an FDA-registered 503B outsourcing facility. Legitimate compounded tirzepatide will have an NDC or facility registration number on the label. Vials lacking any regulatory traceability are a red flag.
Verified Marker
Purity ≥ 98% Confirmed by HPLC
Third-party CoA should show reverse-phase HPLC purity of ≥ 98% and molecular weight confirmation of ~4,813 Da by mass spectrometry. Single-peak chromatogram with no significant impurity peaks.
Verified Marker
Sterility and Endotoxin Testing Passed
CoA should confirm sterility testing per USP <71> and endotoxin levels below 1 EU/mg. These tests are mandatory for any legitimate injectable compounded product.
Verified Marker
Proper Cold Chain Maintained (2–8°C)
The listed research text specifies confirming the vial was refrigerated at 2–8°C during shipping and storage. Once reconstituted, tirzepatide solution should be stored at 2–8°C and used within 28 days. Freezing is prohibited; the product must be discarded if it was previously frozen.
Quality Concern
No Independent CoA Available
Any research supplier unable to provide a third-party Certificate of Analysis with HPLC purity, mass spec, and endotoxin data should be avoided. In-house testing only is insufficient for an injectable compound.
Quality Concern
Cloudy, Discolored, or Particulate Solution
Properly reconstituted tirzepatide should be clear and colorless. The solution must not be used if it is cloudy, discolored, or contains visible particles; these conditions indicate degradation or contamination.